- Clearside Biomedical Inc CLSD announced results from the Extension Study of its OASIS Phase 1/2a trial of CLS-AX (axitinib) administered by suprachoroidal injection via SCS Microinjector in neovascular age-related macular degeneration participants.
- These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data.
- In all participants in the trial, CLS-AX was well tolerated and demonstrated a favorable safety profile across all time points and doses.
- Related: Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data.
- Full extension data showed promising durability, with 67% of participants going at least six months without additional treatment and 50% going beyond six months.
- The company is preparing for and expects to initiate a randomized, controlled, double-masked, Phase 2b trial, dubbed ODYSSEY, in the first quarter of this year, with the primary endpoint readout anticipated in mid-2024.
- Price Action: CLSD shares are up 4.55% at $1.61 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in